Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution
暂无分享,去创建一个
Francesco Favero | Ignacio Varela | Charles Swanton | Paul A Bates | Jennifer Biggs | Nicholas McGranahan | Andrew Rowan | David Nicol | Fabrice André | I. Varela | M. Gerlinger | S. Horswell | J. Larkin | A. Rowan | M. Salm | R. Fisher | B. Phillimore | Sharmin Begum | A. Rabinowitz | B. Spencer‐Dene | S. Gulati | P. Bates | G. Stamp | L. Pickering | M. Gore | S. Hazell | C. Swanton | J. Hsieh | F. André | F. Favero | M. Stares | D. Hrouda | N. McDonald | Jianing Xu | E. Grönroos | Nik Matthews | T. O'brien | D. Nicol | C. Navas | E. D. de Bruin | A. Crockford | Martin Gore | James Larkin | Marco Gerlinger | Mark Stares | Bradley Spencer-Dene | Neil Q McDonald | Eva Grönroos | Nik Matthews | Jianing Xu | Stuart Horswell | Tim O’Brien | Steve Hazell | Gordon Stamp | Ben Phillimore | Sharmin Begum | Rosalie Fisher | Carolina Navas | Lisa Pickering | James J Hsieh | Adam Rabinowitz | Elza C de Bruin | Sakshi Gulati | Virginie Quidville | Maximilian P Salm | Andrew Crockford | David Hrouda | Jennifer Biggs | Virginie Quidville | N. Mcgranahan | Adam H. Rabinowitz | Sakshi Gulati | Mark Stares
[1] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[2] A. F. Bennett,et al. Experimental tests of the roles of adaptation, chance, and history in evolution. , 1995, Science.
[3] Adrian E. Raftery,et al. mclust Version 4 for R : Normal Mixture Modeling for Model-Based Clustering , Classification , and Density Estimation , 2012 .
[4] G. Mills,et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.
[5] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[6] R. Piñeiro,et al. Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis , 2013, PloS one.
[7] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[8] Q. She,et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.
[9] D. Bhattacharya,et al. Faculty Opinions recommendation of Genomic analysis of a key innovation in an experimental Escherichia coli population. , 2012 .
[10] J. Salk. Clonal evolution in cancer , 2010 .
[11] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[12] M. Greaves,et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. , 2011, Blood.
[13] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[14] J. Larkin,et al. Epigenetic regulation in RCC: opportunities for therapeutic intervention? , 2012, Nature Reviews Urology.
[15] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[16] C. Sander,et al. Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.
[17] Aleksey A. Porollo,et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. , 2011, Molecular cell.
[18] M. Greaves,et al. Leukemia in twins: lessons in natural history. , 2003, Blood.
[19] A. Børresen-Dale,et al. Copynumber: Efficient algorithms for single- and multi-track copy number segmentation , 2012, BMC Genomics.
[20] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[21] T. Maffucci,et al. Class II phosphoinositide 3-kinase C2alpha: what we learned so far. , 2011, International journal of biochemistry and molecular biology.
[22] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[23] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Beatty. Replaying life's tape , 2006 .
[25] Z. Szallasi,et al. Parallel evolution of tumour subclones mimics diversity between tumours , 2013, The Journal of pathology.
[26] R. Lenski,et al. Historical contingency and the evolution of a key innovation in an experimental population of Escherichia coli , 2008 .
[27] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[28] C. Sander,et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. , 2013, Cancer cell.
[29] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[30] C. Waddington. Canalization of Development and the Inheritance of Acquired Characters , 1942, Nature.
[31] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[32] Thomas S. Ray,et al. Life's Solution: Inevitable Humans in a Lonely Universe , 2006, Artificial Life.
[33] J. Urano,et al. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells , 2007, Proceedings of the National Academy of Sciences.
[34] E. Boerwinkle,et al. dbNSFP v2.0: A Database of Human Non‐synonymous SNVs and Their Functional Predictions and Annotations , 2013, Human mutation.
[35] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[36] Arianna Di Napoli,et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.
[37] T. Maeda,et al. Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin* , 2008, Journal of Biological Chemistry.
[38] Michael J. Harms,et al. Historical contingency and its biophysical basis in glucocorticoid receptor evolution , 2014, Nature.
[39] W. Samlowski,et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[41] R. Houlston,et al. Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia , 2013, Proceedings of the National Academy of Sciences.
[42] H. Brauch,et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma , 1988, Nature.
[43] J. Haines,et al. Von HippelLindau disease maps to the region of chromosome 3 associated with renal cell carcinoma , 1988, Nature.
[44] Vasyl Pihur,et al. RankAggreg, an R package for weighted rank aggregation , 2009, BMC Bioinformatics.
[45] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[46] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[47] Huanming Yang,et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.
[48] Simion I. Chiosea,et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. , 2013, Cancer discovery.
[49] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[50] J. Hailman. Wonderful Life: The Burgess Shale and the Nature of History, Stephen Jay Gould. W. W. Norton, New York (1989), 347, Price $19.95 (U.S.A.), $27.95 (Canada) , 1991 .
[51] Andrew H. Beck,et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. , 2014, Cancer discovery.
[52] M. Xing,et al. Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity* , 2013, The Journal of Biological Chemistry.
[53] E. Messing,et al. Regulation of receptor for activated C kinase 1 protein by the von Hippel–Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness , 2011, Oncogene.
[54] L. Whyte. Internal factors in evolution. , 1965, The Eugenics review.
[55] Margaret C. Linak,et al. Sequence-specific error profile of Illumina sequencers , 2011, Nucleic acids research.
[56] W. Marston Linehan,et al. Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.
[57] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[58] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[59] B. Krause,et al. S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer , 2011, PloS one.
[60] M. Ferguson-Smith,et al. Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.
[61] R. Arceci. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia , 2012 .
[62] Terry L. Smith,et al. Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.
[63] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[64] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.